Friday, July 10, 2026

Patent intelligence · US

US 12064473

Cancer vaccines targeting Survivin and uses thereof

granted A61KA61K2039/53A61K2039/55527A61K2039/575
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 75
Patent details — US 12064473
Jurisdiction
US
Status
granted
Grant date
Aug 20, 2024
Expiration
Aug 15, 2044
Claims
2
CPC classes
A61K, A61K2039/53, A61K2039/55527, A61K2039/575
View on Google Patents ↗

Quick answer

US 12064473 (Cancer vaccines targeting Survivin and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
2
CPC classes
A61K, A61K2039/53, A61K2039/55527, A61K2039/575, A61K39/00115, A61K39/39

More from Inovio Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12285473

    Cancer vaccines targeting MUC16 and uses thereof

    Inovio Pharmaceuticals, Inc. · Expires Apr 24, 2045

    granted
  2. US 12280108

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Inovio Pharmaceuticals, Inc. · Expires Apr 17, 2045

    granted
  3. US 12251561

    Minimally invasive dermal electroporation device

    Inovio Pharmaceuticals, Inc. · Expires Mar 13, 2045

    granted
  4. US 12240872

    Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

    Inovio Pharmaceuticals, Inc. · Expires Feb 27, 2045

    granted
  5. US 12161706

    Cancer vaccines targeting BORIS and uses thereof

    Inovio Pharmaceuticals, Inc. · Expires Dec 5, 2044

    granted
  6. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Inovio Pharmaceuticals, Inc. · Expires Oct 3, 2044

    granted
  7. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Inovio Pharmaceuticals, Inc. · Expires Aug 1, 2044

    granted

Frequently asked questions

What is US patent 12064473?

US 12064473 (Cancer vaccines targeting Survivin and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted Aug 20, 2024. Expires Aug 15, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12064473?

Inovio Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 75 pharmaceutical patents for this assignee.

When does US 12064473 expire?

Our index shows an expiration date of Aug 15, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.